Immunogenomic Analyses of Pediatric Catatonia

ConditionCatatonia

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age0-17

SponsorRady Pediatric Genomics & Systems Medicine Institute

About this trial

Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 40 children and adolescents who are admitted to Rady Children's Hospital San Diego with a catatonia diagnosis. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve the ability to identify the cause of catatonia and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of catatonia that may inform new treatment for future patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Child/adolescent Ages 0-17 (2) with a diagnosis of catatonia.

Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed to be genetically related to a patient participant

Disqualifiers

Already received any prior whole genome sequencing or exome sequencing.

Unable to approach the family or patient for enrollment.

Unable to obtain informed consent.

They are known to not be genetically related to the child/adolescent patient participant

Trial design

Design model

Single group

Treatments tested in this trial

Genetic: Genomic sequencing and molecular diagnostic results, if any.
Genetic
Genomic sequencing results may be used for diagnosis and treatment of participants.
Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Diagnostic test
Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.

Treatment groups

120 Participants

are divided into 1 treatment group

Group A: Enrollees - WGSExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

Diagnostic rate of whole genome sequencing

Evaluate the impact of whole genome sequencing on diagnostic yield in pediatric catatonia, compared to standard medical workup.

Time frame

2 years

Diagnostic rate of brain reactive autoantibodies

Diagnostic rate of brain reactive autoantibodies via genomic and whole human proteome programmable phage display immunoprecipitation sequencing (PhIP-Seq)

Time frame

2 years

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rady Pediatric Genomics & Systems Medicine Institute

Lead sponsor

Brain & Behavior Research Foundation

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: